Free tool
FAERS Monitor: Teriparatide
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218771 or its brand name (Teriparatide, Teriparatide). Reports on generic versions are filed under their own applications.
Reports
7,158
Serious
4,980
70% of reports
Hospitalization
2,518
Death reported
406
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness525
- nausea523
- fall503
- fatigue487
- back pain474
- arthralgia461
- device malfunction451
- product dose omission issue433
- pain in extremity425
- pain397
- headache391
- device operational issue360
- malaise299
- asthenia280
- dyspnoea238
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 33 |
| 2006 | 16 |
| 2007 | 57 |
| 2008 | 40 |
| 2009 | 52 |
| 2010 | 44 |
| 2011 | 85 |
| 2012 | 307 |
| 2013 | 509 |
| 2014 | 150 |
| 2015 | 142 |
| 2016 | 129 |
| 2017 | 310 |
| 2018 | 437 |
| 2019 | 492 |
| 2020 | 228 |
| 2021 | 185 |
| 2022 | 299 |
| 2023 | 476 |
| 2024 | 986 |
| 2025 | 1,380 |
| 2026 | 791 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,001 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device operational issueSignal | 360 | 268.3 | 241.4 | 87,612 |
| device malfunctionSignal | 451 | 19.0 | 17.3 | 7,637 |
| back painSignal | 474 | 6.0 | 5.5 | 1,990 |
| fallSignal | 503 | 4.4 | 4.1 | 1,360 |
| product dose omission issueSignal | 433 | 4.3 | 4.0 | 1,120 |
| pain in extremitySignal | 425 | 4.2 | 3.9 | 1,064 |
| arthralgiaSignal | 461 | 3.3 | 3.0 | 734 |
| dizzinessSignal | 525 | 3.1 | 2.9 | 760 |
| astheniaSignal | 280 | 2.2 | 2.0 | 183 |
| malaiseSignal | 299 | 2.0 | 1.8 | 152 |
| nausea | 523 | 1.9 | 1.8 | 247 |
| pain | 397 | 1.9 | 1.7 | 173 |
| fatigue | 487 | 1.8 | 1.7 | 192 |
| headache | 391 | 1.8 | 1.7 | 152 |
| dyspnoea | 238 | 1.2 | 1.1 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.